Cambridge Investment Research Advisors
EBS icon

Cambridge Investment Research Advisors’s Emergent Biosolutions EBS Stock Holding History

Cambridge Investment Research Advisors’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,100
Closed -$381K – 3114
2021
Q1 		$381K Buy
4,100
+69
+2% +$7.07K ﹤0.01% 2108
2020
Q4 		$361K Sell
4,031
-72
-2% -$6.61K ﹤0.01% 1999
2020
Q3 		$424K Buy
4,103
+385
+10% +$41.5K ﹤0.01% 1710
2020
Q2 		$294K Buy
+3,718
New +$277K ﹤0.01% 1900

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cambridge Investment Research Advisors's EBS Position: Q2 2021 in Review

Cambridge Investment Research Advisors sold out of Emergent Biosolutions (EBS) in Q2 2021, closing a stake of 4,100 shares — an estimated $381K sold.

Cambridge Investment Research Advisors first reported a position in EBS in Q2 2020 and held it in 4 quarters. The position peaked at $424K in Q3 2020. 290 funds tracked by Wall St. Rank hold EBS as of Q2 2021.

  • Cambridge Investment Research Advisors reported no remaining Emergent Biosolutions position as of Q2 2021 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 4,100 Emergent Biosolutions shares in Q2 2021, an estimated $381K.
  • Cambridge Investment Research Advisors first reported a position in Emergent Biosolutions in Q2 2020 and held it in 4 quarters.
  • Cambridge Investment Research Advisors's Emergent Biosolutions position peaked at $424K in Q3 2020.
  • 290 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2021.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2021, filed 10 Aug 2021.